Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

August 17, 2026

Performance

52-Week Range 26.2% below 52-week high

25.13

15.9652W Low 34.0652W High

1 Week 5.8% below 1-week high

23.711W Low 26.681W High

Zai Lab Limited - American Depositary Shares (ZLAB) traded between $15.96 and $34.06 over the past 52 weeks and last traded at $25.13, 26.2% below its 52-week high. Over the past week it ranged between $23.71 and $26.68.

Past 12 Months

-2.2%

-4.2%

+31.7%

+22.6%

+45.0%

-24.6%

1W -$0.56

1M -$1.10

3M +$6.05

6M +$4.63

YTD +$7.80

1Y -$8.18

ZLAB was -24.6% over the past year, +22.6% over six months, +45.0% year to date, -2.2% in the last week.

12 Months vs Market

ZLAB

-24.6%

DIA

+9.4%

SPY

+15.1%

QQQ

+23.9%

IWM

+14.6%

Over the past 12 months ZLAB returned -24.6% versus DIA (Dow) +9.4%, SPY (S&P 500) +15.1%, QQQ (Nasdaq 100) +23.9% and IWM (Russell 2000) +14.6%.

Volume & Liquidity 0.32× 3-mo avg

Today 301,498 3-mo avg 949.5K

752.3K

836.1K

949.5K

918.4K

YTD

861.6K

859.1K

ZLAB most recently traded 301,498 shares against a 3-month average daily volume of 949.5K.

More News

Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Zai Lab Q2 Earnings Call Highlights ↗

August 07, 2026

Via MarketBeat

Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

August 06, 2026

U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)

August 03, 2026

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026

July 22, 2026

Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas

June 16, 2026

Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer

June 08, 2026

Zai Lab (ZLAB) Q1 2026 Earnings Transcript ↗

June 01, 2026

Zai Lab Announces Changes to Senior Leadership Team

May 21, 2026

Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗

May 21, 2026

Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗

May 21, 2026

Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)

May 11, 2026

Zai Lab Q1 Earnings Call Highlights ↗

May 09, 2026

Via MarketBeat

Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates

May 07, 2026

Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026

April 22, 2026

Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases

April 18, 2026

Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas

April 17, 2026

Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy

April 01, 2026

Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)

March 17, 2026

Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

February 26, 2026

Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026

February 10, 2026

Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference

January 13, 2026

Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors

January 06, 2026